Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
OS Drug Conjugates
New York, New York, United States
- Ownership
- Private
- Development stage
- Other
01
Overview
No direct clinical results reported for OSDC; platform supports multi-agent and tumor-selective release. OS Therapies reports positive Phase 2b results for OST-HER2 (separate program), with ongoing discussions to spin out OSDC technologies into joint ventures with clinical-stage ADC companies
- Therapeutic areas
- Oncology
- Modalities
- Antibody-drug conjugateDrug conjugate
- Industry
- Drug Discovery Services
02
Partnerships
Initiating joint venture discussions with ADC companies in the U.S., China, and globallyParent company partnership with EVERSANA for commercialization, notably of immunotherapy programs
Beyond the preview
Go deeper on OS Drug Conjugates.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on OS Drug Conjugates.